John Theurer Cancer Center Treats First Patient in U.S. with Investigational New Treatment for Brain Cancer

7 mins read

DSP-0390, an investigational new agent developed by Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, is an inhibitor of emopamil-binding protein (EBP), a molecule in cholesterol biosynthesis. DSP-0390 has not been approved by the U.S. Food and Drug Administration nor has its safety and efficacy been established.

“Our bodies need cholesterol to build healthy cells and for those cells to signal one- another,” said Samuel A. Goldlust, M.D., Medical Director of Neuro-Oncology. “But GBM cells can force the production of cholesterol into overdrive, leading to tumor growth and blocking EPB may inhibit this growth.” 

This multicenter, global Phase 1/2 study is planned to enroll 70 patients at five brain tumor centers in the U.S. and Japan.

“Clinical trials in GBM have taught us that traditional treatments are not enough to defeat this challenging tumor,” said George J. Kaptain M.D., Director of Neurosurgical Oncology. “It is a privilege to be able to offer our patients streamlined access to novel, investigational molecularly targeted therapies like DSP -0390, in our ongoing pursuit of treatments to help maximize survival and minimize side effects.”

John Theurer Cancer Center is part of the Georgetown Lombardi Comprehensive Cancer Center. To learn more about this trial (NCT 05023551) and for more information about all brain tumor clinical trials occurring at John Theurer Cancer Center, call 551-996-5266 or visit clinical trials at John Theurer Cancer Center

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s best cancer center, as recognized by U.S. News & World Report.  As a premier cancer center in the State we are also the largest and most comprehensive center dedicated to diagnosis, treatment, management, research, screening, and preventive care as well as survivorship of patients with all types of cancers. The 16 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. John Theurer Cancer Center is part of the Georgetown Lombardi Comprehensive Cancer Center, an NCI designated comprehensive cancer center. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities.  For additional information, please visit www.jtcancercenter.org

About Hackensack Meridian Health
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive, and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research, and life-enhancing care.

Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers – Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune and JFK University Medical Center in Edison; one university teaching hospital – Ocean University Medical Center in Brick; two children’s hospitals – Joseph M. Sanzari Children’s Hospital in Hackensack, K. Hovnanian Children’s Hospital in Neptune; eight community hospitals – Bayshore Medical Center in Holmdel, Old Bridge Medical Center in Old Bridge, Mountainside Medical Center in Montclair, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital – Carrier Clinic in Belle Mead; and two rehabilitation hospitals – JFK Johnson Rehabilitation Institute in Edison and Johnson Rehabilitation Institute in Brick.


Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness center, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 36,000 team members, and 7,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

The network’s notable distinctions include having more top-ranked hospitals than anyone in New Jersey, as recognized by U.S. News & World Report, 2021-22. Hackensack University Medical Center is the only hospital in New Jersey with the #1 adult and children’s hospital rankings.

John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s best cancer center, as recognized by U.S. News & World Report, 2021-22.  This premier cancer center is also the largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. John Theurer Cancer Center is part of Georgetown Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center. 

Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to ensure that patients have access to the highest quality, most individualized cancer care when and where they need it.

The Hackensack Meridian School of Medicine, the first private medical school in New Jersey in more than 50 years, welcomed its first class of students in 2018 to its campus in Nutley and Clifton. The Hackensack Meridian Center for Discovery and Innovation (CDI), housed in a fully renovated state-of-the-art facility, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions.

Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies. To learn more, visit www.hackensackmeridianhealth.org

SOURCE Hackensack University Medical Center